Granules India's subsidiary, GPI, receives USFDA approval for Lisdexamfetamine Dimesylate Capsules, expanding ADHD treatment ...

Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and ...

Hyderabad: Granules India Limited, a vertically integrated Indian pharmaceutical company, has announced that its wholly-owned ...

Granules India receives USFDA approval for its generic Lisdexamfetamine Dimesylate capsules, indicated for the treatment of ...

Granules India receives FDA approval for generic ADHD drug, expanding portfolio and reinforcing presence in treatment space.

Hyderabad: Granules India Limited has announced that the Company's Unit V facility located at Anakapally, Visakhapatnam, ...

The Board of Directors of Granules India Limited, at its meeting held today have approved the financial results of the ...

Granules India reported a drop in third-quarter profit on Friday, hurt by pricing pressure in its key European market.

Quarterly Net Profit at Rs. 90.11 crore in December 2024 down 36.86% from Rs. 142.71 crore in December 2023. EBITDA stands at ...

Granules India’s net profit declined 6 per cent at ₹117 crore in the third quarter ended December 2024 compared to ₹125 crore ...

Granules India's net profit for the third quarter ended December 31, 2024, declined 6% year-on-year to Rs 118 crore. Revenue from operations also decreased. The company's shares were trading down on ...